Academic medicine : journal of the Association of American Medical Colleges
Authors: Boatright D, Edje L, Gruppen LD, Hauer KE, Humphrey HJ, Marcotte K
PLoS medicine
Authors: White JS, Basu S, Kaplan S, Madsen KA, Villas-Boas SB, Schillinger D
JAMA
Authors: Flanagin A, Curfman G, Bibbins-Domingo K
eLife
Authors: Luckett R, Feldman S, Woo YL, Moscicki AB, Giuliano AR, de Sanjose S, Kaufman AM, Leung SOA, Garcia F, Chan K, Bhatla N, Stanley M, Brotherton J, Palefsky J, Garland S, International Papillomavirus Society (IPVS) Policy Committee
Circulation. Cardiovascular imaging
Authors: Nagata Y, Bertrand PB, Baliyan V, Kochav J, Kagan RD, Ujka K, Alfraidi H, van Kampen A, Morningstar JE, Dal-Bianco JP, Melnitchouk S, Holmvang G, Borger MA, Moore R, Hua L, Sultana R, Calle PV, Yum B, Guerrero JL, Neilan TG, Picard MH, Kim J, Delling FN, Hung J, Norris RA, Weinsaft JW, Levine RA
Tobacco control
Authors: Nguyen N, Koester KA, Kim M, Watkins SL, Ling PM
Journal of the American College of Surgeons
Authors: Alexis Colley, Charlie Dharmasukrit, Veronica Yank, Ellis Dillon, Victoria Tang
Volume 7 of Issue 4 | Structural heart : the journal of the Heart Team
Authors: Iskander M, Jamil Y, Forrest JK, Madhavan MV, Makkar R, Leon MB, Lansky A, Ahmad Y
Transcatheter aortic valve replacement (TAVR) is a treatment option for patients with symptomatic severe aortic stenosis across the entire spectrum of surgical risk. Recent trial data have led to the expansion of TAVR into lower-risk patients. With iterative technological advances and successive increases in procedural experience, the occurrence of complications following TAVR has declined. One of the most feared complications remains stroke, and patients consider stroke a worse outcome than death. There has therefore been great interest in strategies to mitigate the risk of stroke in patients undergoing TAVR. In this paper, we will discuss mechanisms and predictors of stroke after TAVR and describe the currently available cerebral embolic protection devices, including their design and relevant clinical studies pertaining to their use. We will also review the current overall evidence base for cerebral embolic protection during TAVR and ongoing randomized controlled trials. Finally, we will discuss our pragmatic recommendations for the use of cerebral embolic protection devices in patients undergoing TAVR.
View on PubMed
Drug and alcohol dependence
Authors: Tsui JI, Lum PJ, Taylor LE, Mehta SH, Feinberg J, Kim AY, Norton BL, Niu J, Heo M, Arnsten J, Pericot-Valverde I, Thomas A, Blalock KL, Radick A, Murray-Krezan C, Page K, Litwin AH, HERO Study Group
Urology
Authors: Hampson LA, Shaw N, Breyer BN, Walter LC, Sudore RL, Cooperberg MR, Baussan C, Quanstrom K, Elaine Allen I, Dohan D
